Impact of CMV Status on HIV Viral Load Decay

Hospices Civils de Lyon345 enrolled

Overview

Background: Cytomegalovirus (CMV) infection is usually observed among patients with HIV infection. No study to date has investigated the impact of CMV infection on HIV viral load decay during antiretroviral therapy. Methods: 345 consecutive HIV patients coinfected (N=300) or not (N=45) with CMV were enrolled. Clinical, biological and virological data were collected from HIV antiretroviral therapy initiation to the day of HIV viral load undetectability if any.

Study Type

OBSERVATIONAL

Enrollment

345

Conditions

Hiv

Interventions

HIV antiretroviral therapyDRUG

HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV patients starting an antiretroviral therapy * CMV serology available at antiretroviral therapy initiation * HIV viral load assessed at each follow-up visit after treatment initiation Exclusion Criteria: * HIV antiretroviral treatment initiation before June 2005

Locations (1)

Croix-Rousse Hospital, Hospices Civils de Lyon

Lyon, France

Outcomes

Primary Outcomes

HIV viral load undetectability

HIV viral load was assessed during the follow-up visits after the initiation of antiretroviral therapy. HIV undetectability was defined by an HIV-RNA level \<50 copies/mL.

Time frame: From date of HIV therapy initiation until the date of HIV viral load undetectability (12 weeks in average after treatment initiation)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.